<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057065</url>
  </required_header>
  <id_info>
    <org_study_id>LS2021037</org_study_id>
    <nct_id>NCT05057065</nct_id>
  </id_info>
  <brief_title>A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB</brief_title>
  <official_title>Disease Progression and Intervention of Chronic HepatitisB Based on Diabetes and Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Ren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HBV(hepatitis B virus) with metabolic comorbidities may accelerate liver disease progression&#xD;
      and increase the risk of HCC(Hepatocellular Carcinoma)development. It is reported combination&#xD;
      of metabolic diseases and CHB is associated with substantially increased rates of liver&#xD;
      cirrhosis and secondary liver-related events compared to CHB alone. Consequently, hepatitis B&#xD;
      patients with metabolic comorbidities warrant particular attention in disease surveillance&#xD;
      and evaluation of treatment indications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate the impact of metabolic disease on the progression of chronic hepatitis B&#xD;
&#xD;
        -  To observe HBsAg/HBeAg/HBV DNA changes /HBsAg seroconversion&#xD;
&#xD;
        -  To determine high rates of Liver Cirrhosis and Hepatocellular Carcinoma&#xD;
&#xD;
      Group 1 : CHB with diabetes Group 2 : CHB with hyperlipemia Group 3 : CHB without metabolic&#xD;
      diseases&#xD;
&#xD;
      Study Duration (in months) 24 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of NAs therapy</measure>
    <time_frame>2 year</time_frame>
    <description>We will follow up patients every six months and all patients with a history of hepatitis B will be tested for HBsAg(+) and HBD-DNA.The curative effect was evaluated by observing the changes of serological indexes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of liver fibrosis and cirrhosis</measure>
    <time_frame>2 year</time_frame>
    <description>We will follow up patients every six months and all patients() with a history of hepatitis B will be tested for FibroScan. The influence of metabolic diseases on the progression of hepatitis B was evaluated by comparing the changes of liver hardness between groups（Hyperlipidemia，Diabetes and CHB without metabolic disease）</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Hyperlipidemia</arm_group_label>
    <description>HBsAg(+) patients&#xD;
TC&gt;5.17mmol/L（200mg/dl）and（or）TG&gt;2.3mmol/L（200mg/dl）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetes</arm_group_label>
    <description>HBsAg(+) patients&#xD;
FPG&gt;126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHB without metabolic disease</arm_group_label>
    <description>HBsAg(+) patients&#xD;
without diabetes/ obesity/hyperlipidemia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis B patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B (positive HBsAg for at least 6 months prior to NA therapy start)&#xD;
&#xD;
          -  Patients on-treatment with NAs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with immunosuppressors (including systemic corticosteroids) or&#xD;
             anti-neoplastic treatment (including radiation therapy) &lt;=6 months prior to the first&#xD;
             dose of study drug or the expectation that such treatment will be needed at any time&#xD;
             during the study.&#xD;
&#xD;
          -  History of depression or uncontrolled psychiatric disorders&#xD;
&#xD;
          -  Subjects protected by law or not in a position to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HONG REN, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HONG REN, Prof.</last_name>
    <phone>8613983888786</phone>
    <email>renhong0531@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DACHUAN CAI, Dr.</last_name>
    <phone>8613883596197</phone>
    <email>dachuancai@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 2nd affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HONG REN</last_name>
      <phone>+8613983888786</phone>
      <email>renhong0531@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>DACHUAN CAI</last_name>
      <phone>+8613883596197</phone>
      <email>dachuancai@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>HONG REN, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Hong Ren</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>metabolic diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

